EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation

Srividhya Senthil iD, Abdul Moothedath iD, Jane Elizabeth Potter iD, Heather Mcgrath Wilkinson, Eden Whiteside, Ramya Nataraj, Omima Mustafa, Claire Horgan iD, Denise Bonney, Sarah Brett, Rob Wynn

Pediatric Transplantation · 2025

DOI: 10.1111/petr.70228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Srividhya Senthil und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation, Royal Manchester Children's Hospital, Manchester, UK. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Receptors, Fc, Recombinant Fusion Proteins, Stem Cell Transplantation. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The use of romiplostim, a thrombopoietin agonist, has increased in the last decade for the treatment of immune mediated thrombocytopenia and severe aplastic anemia. Its utility has been explored in the management of delayed platelet engraftment and secondary platelet failure during stem cell transplant (SCT), but its use has remained largely anecdotal in pediatric allogeneic SCT.

Methods

In this single centre, retrospective study we report the largest pediatric SCT cohort use of romiplostim.

Results

Romiplostim was used in 17 children for several indications, principally including poor graft function (PGF) and immune‐mediated cytopenia (IMC), including multi‐lineage cytopenia. The overall response rate (ORR) was 76.5% and the median time to achieve OR was 42 days. No toxicity was observed with romiplostim including marrow fibrosis, clonal evolution and thrombosis with a median follow‐up of 18 months. Romiplostim averted the need for second allogeneic SCT in two patients with late graft failure and the need for stem cell boost (SCB) in three patients.

Conclusion

We propose that romiplostim can be safely used in the cytopenia in pediatric SCT to good effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationReceptors, FcRecombinant Fusion ProteinsStem Cell TransplantationThrombopoietinAdolescentChildChild, PreschoolFemaleHumansInfantMaleFollow-Up StudiesRetrospective StudiesThrombocytopeniaTransplantation, HomologousTreatment Outcome

Substanzen

Receptors, FcRecombinant Fusion ProteinsromiplostimThrombopoietin

Autor:innen und Institutionen

  • Department of Bone Marrow Transplantation, Royal Manchester Children's Hospital, Manchester, UK.
  • Department of Pharmacy, Royal Manchester Children's Hospital, Manchester, UK.

ORCID-Profile: Srividhya Senthil, Abdul Moothedath, Jane Elizabeth Potter, Claire Horgan

Zitieren

APA

Senthil, S., Moothedath, A., Potter, J. E., Wilkinson, H. M., Whiteside, E., Nataraj, R., Mustafa, O., Horgan, C., Bonney, D., Brett, S., & Wynn, R. (2025). Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.70228

Vancouver

Senthil S, Moothedath A, Potter JE, Wilkinson HM, Whiteside E, Nataraj R, et al. Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation. Pediatric Transplantation. 2025. doi:10.1111/petr.70228

BibTeX
@article{Senthil2025,
  author = {Senthil, Srividhya and Moothedath, Abdul and Potter, Jane Elizabeth and Wilkinson, Heather Mcgrath and Whiteside, Eden and Nataraj, Ramya and Mustafa, Omima and Horgan, Claire and Bonney, Denise and Brett, Sarah and Wynn, Rob},
  title = {Utility and Safety of Romiplostim in Pediatric Allogeneic Stem Cell Transplantation},
  journal = {Pediatric Transplantation},
  year = {2025},
  doi = {10.1111/petr.70228}
}
Kostenlos starten →